VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Bicycle Therapeutics Executive Compensation (FY25)

BCYC · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Kevin Lee
Latest say-on-pay support
=
June 17, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Bicycle Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 1, 2026Latest filing (8-K): June 18, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Bicycle Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
226 figures on this page: 219 cited to the filing that reported them, 7 calculated from figures it prints. See the citations

More on Bicycle Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kevin Lee: $4,857,218 → $6,341,473 (30.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bicycle Therapeutics' chief executive and what were they paid?
Kevin Lee, Chief Executive Officer, received $6,341,473 in total compensation for fiscal 2025. Lee's total was 30.6% higher than the $4,857,218 reported for fiscal 2024.
What was Bicycle Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 98.4% of votes cast for or against in favor at the meeting held June 17, 2026 for fiscal 2025.
Which companies are in Bicycle Therapeutics' peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., Arcus Biosciences, Inc., Arvinas, Inc., Beam Therapeutics, Inc. and Blueprint Medicines Corporation, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Lee
Chief Executive Officer
◇—◇◇◇—◇◇
Alistair Milnes
Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Lee
Chief Executive Officer
◇◇◇◇◇—◇◇
Alethia Young
Chief Financial Officer
◇◇—◇◇—◇◇
Santiago Arroyo
Chief Development Officer
◇——◇◇—◇◇
Alistair Milnes
Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Lee
Chief Executive Officer
◇—◇◇◇—◇◇
Santiago Arroyo
Chief Development Officer
◇—◇◇◇—◇◇
Alistair Milnes
Chief Operating Officer
◇—◇◇◇—◇◇
D.Sc. Michael Hannay
Chief Product and Supply Chain Officer
◇—◇◇◇—◇◇
Alethia Young
Chief Financial Officer
◇◇◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Lee
Chief Executive Officer
◇—◇◇◇—◇◇
Michael Skynner
Chief Technology Officer (2025); Chief Scientific Officer (effective January 1, 2026)
◇—◇◇◇—◇◇
Alistair Milnes
Chief Operating Officer (2025); Chief Corporate Development Officer (effective March 17, 2026)
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alistair MilnesRSU——————◇
Alistair MilnesOPTION——————◇
Kevin LeeRSU——————◇
Kevin LeeOPTION——————◇
Michael SkynnerOPTION——————◇
Michael SkynnerRSU——————◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Kevin LeeOption◇—◇January 2, 2035
RSU◇◇——
Option◇—◇January 2, 2034
RSU◇◇——
Option◇—◇January 3, 2033
RSU◇◇——
RSU◇◇——
Option◇—◇January 3, 2032
Alistair MilnesOption◇—◇January 2, 2035
Option◇—◇January 2, 2034
RSU◇◇——
RSU◇◇——
Option◇—◇January 3, 2033
RSU◇◇——
Option◇—◇January 3, 2032
RSU◇◇——
Michael SkynnerOption◇—◇January 2, 2035
RSU◇◇——
Option◇—◇January 2, 2034
RSU◇◇——
Option◇—◇January 3, 2033
RSU◇◇——
RSU◇◇——
Option◇—◇January 3, 2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Pierre Legault, MBA, CPA
◇◇◇——◇◇
Jose-Carlos Gutierrez-Ramos, Ph.D
◇◇◇——◇◇
Alessandro Riva, M.D
◇◇◇———◇
Janice Bourque, MBA
◇◇◇——◇◇
Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP
◇◇◇——◇◇
Stephen Sands, MBA
◇◇◇——◇◇
Sir Gregory Winter, FRS
◇◇◇———◇
Richard Kender, MBA
◇◇◇——◇◇
Roger Dansey, M.D
◇◇◇——◇◇
Felix J. Baker, Ph.D
Board chair
◇◇◇———◇
Herve Hoppenot
◇◇◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Agios Pharmaceuticals, Inc. AGIO
  • Arcus Biosciences, Inc. RCUS
  • Arvinas, Inc. ARVN
  • Beam Therapeutics, Inc. BEAM
  • Blueprint Medicines Corporation BPMC
  • Cogent Biosciences, Inc. COGT
  • Deciphera Pharmaceuticals, Inc. DCPH
  • ImmunoGen, Inc. IMGN
  • Intellia Therapeutics, Inc. NTLA
  • Ionis Pharmaceuticals, Inc. IONS
  • Karuna Therapeutics, Inc. KRTX
  • Revance Therapeutics, Inc. RVNC
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Sage Therapeutics, Inc. SAGE
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals, Inc. SNDX
  • TG Therapeutics, Inc. TGTX
  • Xencor, Inc. XNCR
  • Zentalis Pharmaceuticals, Inc. ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 17, 2026=◇◇◇
2024June 17, 2025=◇◇◇
2023May 16, 2024=◇◇◇
2022June 13, 2023=◇◇◇
2021June 27, 2022=◇◇◇
2020June 28, 2021=◇◇◇
2019June 29, 2020=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Kevin Lee (Chief Executive Officer), FY2025 total compensation $6,341,473 (base salary $862,339) [exec_comp, SEC accession 0001104659-26-046806, filed 2026-04-22]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Bicycle Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bicycle Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bicycle Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Bicycle Therapeutics' disclosed peer group is defensible, who names Bicycle Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
226 figures on this page: 219 cited to the filing that reported them, 7 calculated from figures it prints.
219 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001104659-26-075451
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-046806
    Summary Compensation Table
  3. 0001104659-25-060316
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001558370-25-005258
  5. 0001104659-24-062503
  6. 0001104659-23-071024
  7. 0001104659-22-074753
  8. 0001104659-21-086292
  9. 0001104659-20-077995
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bicycle Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BCYC (accessed 2026).
Short form: data: Velarion

The paid brief for Bicycle Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bicycle Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Bicycle Therapeutics discloses

The companies named in BCYC's own disclosed peer group.

Agios Pharmaceuticals, Inc.Arcus Biosciences, Inc.Arvinas, Inc.Beam Therapeutics, Inc.Blueprint Medicines CorporationCogent Biosciences, Inc.Deciphera Pharmaceuticals, Inc.ImmunoGen, Inc.Intellia Therapeutics, Inc.Ionis Pharmaceuticals, Inc.Karuna Therapeutics, Inc.Revance Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.Sage Therapeutics, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.TG Therapeutics, Inc.Xencor, Inc.Zentalis Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy